Cholesterol Homeostasis

Description

Cholesterol homeostasis in the brain involves the tightly regulated synthesis, transport, and turnover of cholesterol, which is essential for membrane integrity, synaptic vesicle formation, lipid raft assembly, and myelin maintenance. Unlike peripheral tissues, the brain cannot import cholesterol across the blood-brain barrier and depends entirely on local synthesis -- primarily by astrocytes, which package cholesterol into ApoE-containing lipoproteins for delivery to neurons via LRP1 and ApoER2 receptors. Neurons metabolize excess cholesterol to 24S-hydroxycholesterol (via CYP46A1) for export.

In Alzheimer's disease, cholesterol homeostasis is disrupted at multiple levels, making it one of the most convergent metabolic axes. The APP fragment C99 contains a cholesterol-binding domain and functions as a cholesterol sensor at mitochondria-associated ER membranes (MAMs). When C99 accumulates (due to gamma-secretase processing failure or BACE1 hyperactivity), it signals false cholesterol deficiency, triggering SREBP-mediated cholesterol synthesis and ACAT1-mediated esterification in a futile lipid cycle. ApoE4 cannot properly accept cholesterol from ABCA1 transporters due to its pathological "molten globule" domain interaction, creating a transport bottleneck that starves neuronal endolysosomal membranes. Caveolin-1, a scaffolding protein for membrane lipid rafts, mediates non-vesicular cholesterol transport via the RELCH pathway; its loss destabilizes v-ATPase assembly and impairs synaptic receptor recycling.

Cholesterol deficiency at lipid rafts has cascading effects: v-ATPase requires cholesterol-rich raft microdomains for proper V0/V1 subunit assembly, and lipid rafts serve as essential platforms for synaptic receptor stabilization. Cholesterol crystal accumulation in microglia (from failed efflux) triggers lysosomal damage and NLRP3 inflammasome activation, linking cholesterol dysregulation to neuroinflammation.

Convergence Nodes

• Endosomal Nexus -- Cholesterol transport failure disrupts endosomal membrane composition and receptor sorting
• APOE4 Hub -- APOE4 hypolipidation creates a systemic cholesterol transport deficit
• Compensatory Paradigm Nexus -- C99 cholesterol sensing represents a feedback loop that becomes pathologically reinforced

Prize Entrants

• Estela Area-Gomez -- Defined AD as a lipid disorder driven by C99 cholesterol sensor dysfunction at MAMs; demonstrated ACAT1-mediated futile lipid cycling
• Brian Head -- Showed Caveolin-1 gene therapy restores membrane lipid raft scaffolding and RELCH-mediated cholesterol transport, rescuing v-ATPase function and autophagic flux
• Ari Rappoport -- Proposed neural cholesterol deficiency from failed astrocyte-to-neuron transport as the primary AD mechanism
• Daniel Michaelson -- Demonstrated ApoE4 molten globule conformation blocks ABCA1-mediated lipidation; developed ABCA1 agonist CS6253 as therapeutic; showed dietary ALA restores brain lipid balance
• Brenda Aske -- Identified cholesterol crystal-induced lysosomal damage and v-ATPase inhibition in LDAM microglia

External Scientists

• Hussein Yassine -- Brain DHA and cholesterol metabolism in APOE4 carriers
• Julia TCW -- iPSC-derived cholesterol metabolic profiling across ApoE genotypes
• Kimberley Bruce -- Lipid transport and cholesterol metabolism in neurodegeneration

Key Open Questions

• Is the primary cholesterol defect in AD a failure of astrocyte synthesis, ApoE-mediated transport, or neuronal uptake/utilization?
• Can ABCA1 agonists or Caveolin-1 gene therapy restore cholesterol delivery to rescue v-ATPase assembly and autophagic flux?
• Does the C99 cholesterol sensor model explain why BACE inhibitors failed clinically -- by paradoxically removing C99 and disrupting the cholesterol sensing feedback?
• How does brain cholesterol homeostasis interact with peripheral lipid metabolism and statin use?